TIL Instil Bio
Price Chart
Executive Summary
Instil Bio reported its Q4 and full-year 2025 financial results, showing a reduced net loss compared to the prior year despite declining cash reserves. The company discontinued development of AXN-2510 and is now focusing on external growth through acquisitions and in-licensing, with a cash runway expected to fund operations beyond 2027.
Key Financial Metrics
Actionable Insight
Traders should monitor for potential M&A or in-licensing announcements, which could catalyze upside. However, the lack of an internal pipeline and declining cash raise execution risk despite improved cost discipline.
Key Facts
- Net loss for full year 2025 was $71.37 million ($10.70 per share), improved from $74.14 million ($11.39 per share) in 2024.
- Cash, cash equivalents, restricted cash, and marketable securities declined to $76.3 million as of December 31, 2025, from $115.1 million a year earlier.
- The company discontinued AXN-2510 development and terminated its collaboration with ImmuneOnco Biopharmaceuticals.
- Instil is now pursuing acquisitions and in-licensing opportunities to build a new pipeline.
- Non-GAAP net loss per share improved to $6.91 in 2025 from $7.59 in 2024.
Financial Impact
Cash position decreased by $38.8 million year-over-year; full-year net loss decreased by $2.77 million. Non-GAAP net loss improved by $3.33 million.
Risk Factors
- No current internal pipeline following discontinuation of AXN-2510.
- Execution risk in identifying and closing external innovation deals.
- Dilution risk if future transactions are funded through equity.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3263677 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 15, 2026
25d ago
|
8-K
| $8.07 $8.18 | ▲ +1.36% | ▲ +0.40% | $8.08 (+0.12%) |
|
May 15, 2026
25d ago
|
Press Release
| $8.07 $8.18 | ▲ +1.36% | ▲ +0.40% | $8.08 (+0.12%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $8.13 $7.84 | ▼ −3.57% | ▼ −3.97% | $8.08 (−0.62%) |
|
Apr 3, 2026
9w ago
|
8-K
| $8.46 $8.36 | ▼ −1.24% | ▼ −5.38% | $8.08 (−4.49%) |
|
Mar 27, 2026
10w ago
|
Press Release
| $7.79 $8.46 | ▲ +8.60% | ▲ +4.74% | $8.08 (+3.72%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access